Piramal Invests $55M to Expand API Mfg. Capabilities
10.09.17
Will add multi-purpose plants, with more than 270kL of total capacity
Piramal Pharma Solutions (PPS), a contract development and manufacturing organization (CDMO) is investing $55 million across its sites in North America & Asia, to expand its API manufacturing capabilities and capacities.
Part of this investment will go into new, multi-purpose plants, with more than 270kL of total capacity, to support the current pipeline of approximately 80 late-stage programs PPS is currently assisting partners with. PPS will also expand its potency footprint (new Occupational Exposure Limit: ≥10 ng/m3) at its plant in Riverview, MI, while augmenting early development capabilities out of Ennore, India through additions of GMP kilo labs and a pilot plant. In Europe, the company will add early development capabilities in both, drug substance and drug product, at its Morpeth, UK facility. Support functions such as analytical capabilities, R&D infrastructure, automation, and IT systems will also be expanded at all API sites.
Vivek Sharma, chief executive officer of Piramal Pharma Solutions said, "We are committed towards investing in our customers' future needs. With these investments, we can now support the commercialisation of our pipeline of over 80 programs that are at Phase II or beyond, while allowing us additional capacity for future partnerships." He added: "There has been significant customer interest in our 'integrated' offerings, and we are pleased to have over 60 integrated programs at PPS across all phases of drug development. We thank our customers for their trust and support and promise to continue the focus on the three pillars that made us their Partner of Choice: Customer Centricity, Quality, and Innovation."
Part of this investment will go into new, multi-purpose plants, with more than 270kL of total capacity, to support the current pipeline of approximately 80 late-stage programs PPS is currently assisting partners with. PPS will also expand its potency footprint (new Occupational Exposure Limit: ≥10 ng/m3) at its plant in Riverview, MI, while augmenting early development capabilities out of Ennore, India through additions of GMP kilo labs and a pilot plant. In Europe, the company will add early development capabilities in both, drug substance and drug product, at its Morpeth, UK facility. Support functions such as analytical capabilities, R&D infrastructure, automation, and IT systems will also be expanded at all API sites.
Vivek Sharma, chief executive officer of Piramal Pharma Solutions said, "We are committed towards investing in our customers' future needs. With these investments, we can now support the commercialisation of our pipeline of over 80 programs that are at Phase II or beyond, while allowing us additional capacity for future partnerships." He added: "There has been significant customer interest in our 'integrated' offerings, and we are pleased to have over 60 integrated programs at PPS across all phases of drug development. We thank our customers for their trust and support and promise to continue the focus on the three pillars that made us their Partner of Choice: Customer Centricity, Quality, and Innovation."
